NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02998528,A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT02998528,CheckMate 816,COMPLETED,"The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating resectable NSCLC.

This study has multiple primary endpoints.",YES,Non Small Cell Lung Cancer,BIOLOGICAL: Nivolumab|DRUG: Cisplatin|DRUG: Vinorelbine|DRUG: Gemcitabine|DRUG: Docetaxel|DRUG: Pemetrexed|DRUG: Carboplatin|DRUG: Paclitaxel|BIOLOGICAL: Ipilimumab,"Event-Free Survival (EFS), Event-free survival (EFS) is defined as the length of time from randomization to any of the following events: any progression of disease precluding surgery, progression or recurrence disease based on blinded independent central review (BICR) assessment per response evaluation criteria in solid tumors (RECIST) 1.1 after surgery, or death due to any cause. Participants who don't undergo surgery for reason other than progression will be considered to have an event at progression or death. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression)., From randomization to disease progression, reoccurrence, or death due to any cause. (Up to a median of 30 months)|Pathologic Complete Response (pCR) Rate, Pathologic complete response (pCR) rate is defined as the number of randomized participants with absence of residual tumor in lung and lymph nodes as evaluated by blinded independent pathological review (BIPR)., From randomization up to a median of 30 months after randomization.","Major Pathologic Response (MPR) Rate, Major pathologic response (MPR) rate is defined as number of randomized participants with \</= 10% residual tumor in lung and lymph nodes as evaluated by blinded independent pathological review (BIPR). Viable tumors in situ carcinoma should not be included in MPR calculation., From randomization up to a median of 30 months after randomization.|Overall Survival (OS), Overall survival (OS) is defined as the time between the date of randomization and the date of death. OS will be censored on the last date a participant was known to be alive., From randomization to the date of death|Time to Death or Distant Metastases (TTDM), TTDM is defined as the time between the date of randomization and the first date of distant metastasis or the date of death in the absence of distant metastasis. Distant metastasis is defined as any new lesion that is outside of the thorax using blinded independent central review (BICR) according to response evaluation criteria in solid tumors (RECIST) 1.1. Patients who have not developed distant metastasis or died at the time of analysis will be censored on the date of their last evaluable tumor assessment., From randomization to the first date of distant metastasis or the date of death in the absence of distant metastasis (Up to a median of 30 months)",,Bristol-Myers Squibb,Ono Pharmaceutical Co. Ltd,ALL,"ADULT, OLDER_ADULT",PHASE3,505,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CA209-816|2016-003536-21,2017-03-04,2021-09-08,2024-12-06,2016-12-20,2022-09-28,2025-01-24,"Local Institution - 0121, Glendale, Arizona, 85308, United States|Local Institution - 0081, Los Angeles, California, 90017, United States|Local Institution - 0025, Denver, Colorado, 80218, United States|Local Institution - 0007, Plainville, Connecticut, 06062, United States|Local Institution - 0173, Hollywood, Florida, 33021, United States|Local Institution - 0136, Miami, Florida, 33136, United States|Local Institution - 0054, Orlando, Florida, 32804, United States|Orlando Health, Inc., Orlando, Florida, 32806, United States|Indian River Medical Center, Vero Beach, Florida, 32960, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, 30060, United States|Local Institution - 0015, Chicago, Illinois, 60611, United States|Local Institution - 0002, Chicago, Illinois, 60637, United States|Illinois Cancer Specialists, Niles, Illinois, 60714, United States|Local Institution - 0171, Fort Wayne, Indiana, 46804, United States|Local Institution - 0170, Lexington, Kentucky, 40536, United States|Local Institution - 0186, Louisville, Kentucky, 40202, United States|University Medical Center New Orleans, New Orleans, Louisiana, 70112, United States|Local Institution - 0151, Baltimore, Maryland, 21237, United States|Local Institution - 0001, Baltimore, Maryland, 21287, United States|Local Institution - 0008, Boston, Massachusetts, 02215, United States|Southcoast Center For Cancer, Fairhaven, Massachusetts, 02719, United States|Local Institution - 0006, Newton, Massachusetts, 02459, United States|Local Institution - 0012, Detroit, Michigan, 48202-2608, United States|Local Institution - 0090, Hattiesburg, Mississippi, 39401, United States|St Vincent Frontier Cancer Center, Billings, Montana, 59102, United States|Local Institution - 0032, Las Vegas, Nevada, 89128, United States|Local Institution - 0009, Hackensack, New Jersey, 07601, United States|Valley Hospital Luckow Pavili, Westwood, New Jersey, 07675, United States|Local Institution - 0027, Albany, New York, 12208, United States|Local Institution - 0011, New York, New York, 10016, United States|Local Institution - 0140, High Point, North Carolina, 27262, United States|Christ Hospital, Cincinnati, Ohio, 45219, United States|MetroHealth Medical Center, Cleveland, Ohio, 44109, United States|Local Institution - 0149, Zanesville, Ohio, 43701, United States|Kaiser Permanente, Portland, Oregon, 97227, United States|Local Institution - 0139, Portland, Oregon, 97239, United States|Local Institution - 0010, Philadelphia, Pennsylvania, 19111, United States|Local Institution - 0018, Pittsburgh, Pennsylvania, 15212, United States|Local Institution - 0013, Charleston, South Carolina, 29414, United States|Local Institution - 0021, Charleston, South Carolina, 29425, United States|Local Institution - 0146, Greenville, South Carolina, 29607, United States|Local Institution - 0092, Nashville, Tennessee, 37203, United States|Local Institution - 0005, Nashville, Tennessee, 37232, United States|Local Institution - 0035, Austin, Texas, 78745, United States|Texas Oncology, Bedford, Texas, 76022, United States|Local Institution - 0153, Fort Bliss, Texas, 79918, United States|Local Institution - 0106, Houston, Texas, 77090, United States|Southwest Cancer Center, Lubbock, Texas, 79415, United States|Texas Cancer Center - Sherman, Sherman, Texas, 75090-0504, United States|Local Institution - 0143, Tyler, Texas, 75701, United States|Local Institution - 0026, Waco, Texas, 76712, United States|Intermountain Medical Center, Murray, Utah, 84107, United States|Southwest Regional Cancer Clinic, Saint George, Utah, 84770, United States|Local Institution - 0003, Salt Lake City, Utah, 84112, United States|Local Institution - 0135, Burlington, Vermont, 05405, United States|Local Institution - 0125, Fairfax, Virginia, 22031, United States|Local Institution - 0198, Fredericksburg, Virginia, 22408, United States|Local Institution - 0022, Capital Federal, Buenos Aires, 1426, Argentina|Local Institution - 0023, Ciudad Autonoma De Buenos Aire, Buenos Aires, 1181, Argentina|Local Institution - 0079, Brasilia, Distrito Federal, 70200-730, Brazil|Local Institution - 0077, Belo Horizonte, Minas Gerais, 30130-090, Brazil|Local Institution - 0076, Ijui, RIO Grande DO SUL, 98700-000, Brazil|Local Institution - 0073, Porto Alegre, RIO Grande DO SUL, 90610-000, Brazil|Fundacao Pio Xii Hosp Cancer De Barretos, Barretos, Sao Paulo, 14784-400, Brazil|Local Institution - 0075, Rio de Janeiro, 22793-080, Brazil|Local Institution - 0095, Gatineau, Quebec, J8P 7H2, Canada|Local Institution - 0138, Montreal, Quebec, H2X 0A9, Canada|Local Institution - 0017, Montreal, Quebec, H4A 3J1, Canada|Local Institution - 0052, Trois-Rivieres, Quebec, G8Z 3R9, Canada|Local Institution - 0016, Saskatoon, Saskatchewan, S7N 4H4, Canada|Local Institution - 0161, Beijing, Beijing, 100142, China|Local Institution, Beijing, Beijing, 100730, China|Local Institution - 0156, Beijing, Beijing, 100853, China|Local Institution - 0190, Guangzhou, Guangdong, 510095, China|Local Institution - 0192, Changsha, Hunan, 410008, China|Local Institution - 0175, Changsha, Hunan, 410013, China|Local Institution - 0193, Changsha, Hunan, 410013, China|Local Institution - 0179, Nanchang, Jiangxi, 330006, China|Local Institution - 0166, Nanchang, Jiangxi, 330200, China|Local Institution, Changchun, Jilin, 130012, China|Local Institution - 0159, XiAn, Shan1xi, 710061, China|Local Institution - 0180, Xian, Shan3xi, 710038, China|Local Institution - 0160, Shanghai, Shanghai, 200032, China|Local Institution - 0178, Chengdu, Sichuan, 610041, China|Local Institution - 0163, Tianjin, Tianjin, 300060, China|Local Institution - 0189, Hangzhou, Zhejiang, 310003, China|Local Institution - 0183, Hangzhou, Zhejiang, 310016, China|Local Institution - 0182, Hangzhou, Zhejiang, 310022, China|Local Institution - 0165, Shanghai, 200030, China|Local Institution - 0059, Marseille Cedex 20, 13915, France|Local Institution - 0112, Paris Cedex 5, 75248, France|Local Institution - 0060, Paris, 75018, France|Local Institution - 0064, Pierre Benite Cedax, 69495, France|Local Institution - 0061, Rennes Cedex 9, 35033, France|Local Institution - 0113, Strasbourg, 67100, France|Local Institution - 0058, Toulouse, 31059, France|Local Institution - 0062, Tours Cedex 09, 37044, France|Local Institution - 0019, Athens, 11527, Greece|Local Institution - 0122, Thessaloniki, 57001, Greece|Local Institution, Budapest, 1125, Hungary|Local Institution, Szekesfehervar, 8000, Hungary|Local Institution - 0068, Bari, 70124, Italy|Local Institution - 0080, Genova, 16132, Italy|Local Institution - 0070, Perugia, 06129, Italy|Local Institution - 0066, Ravenna, 48121, Italy|Local Institution - 0067, Roma, 00149, Italy|Local Institution - 0131, Nagoya-shi, Aichi, 4640021, Japan|Local Institution - 0118, Kashiwa-shi, Chiba, 2778577, Japan|Local Institution - 0111, Kitakyushu-shi, Fukuoka, 8078555, Japan|Local Institution - 0110, Fukushima-shi, Fukushima, 9601295, Japan|Local Institution - 0109, Hiroshima-Shi, Hiroshima, 7348551, Japan|Local Institution - 0147, Sapporo-shi, Hokkaido, 0030804, Japan|Local Institution - 0133, Kobe-shi, Hyogo, 6500047, Japan|Local Institution - 0123, Yokohama-shi, Kanagawa, 2418515, Japan|Local Institution - 0148, Sendai-shi, Miyagi, 9800873, Japan|Local Institution - 0127, Osaka-shi, Osaka, 5418567, Japan|Local Institution - 0119, Sakai-shi, Osaka, 5918555, Japan|Local Institution - 0132, Sunto-gun, Shizuoka, 4118777, Japan|Local Institution - 0126, Bunkyo-ku, Tokyo, 1138431, Japan|Local Institution - 0120, Shinjuku-ku, Tokyo, 1600023, Japan|Local Institution - 0108, Osaka, 589-8511, Japan|Local Institution - 0124, Tokyo, 113-8603, Japan|Local Institution - 0097, Busan, 49267, Korea, Republic of|Local Institution - 0098, Hwasun, 58128, Korea, Republic of|Local Institution - 0105, Seoul, 08308, Korea, Republic of|Local Institution - 0042, Amsterdam, 1066 CX, Netherlands|Local Institution - 0043, Groningen, 9700RB, Netherlands|Local Institution - 0050, Craiova, 200347, Romania|Local Institution - 0051, Romania, 400015, Romania|Local Institution - 0069, Sector 2, 022328, Romania|Local Institution - 0028, Barcelona, 08035, Spain|Local Institution - 0029, Madrid, 28041, Spain|Local Institution - 0031, Majadahonda - Madrid, 28222, Spain|Local Institution - 0102, New Taipei City, 235, Taiwan|Local Institution - 0107, Taichung, 407219, Taiwan|Local Institution - 0099, Taipei, 11031, Taiwan|Local Institution - 0100, Taipei, 112, Taiwan|Local Institution - 0093, Adana, 01060, Turkey|Local Institution - 0084, Ankara, 06100, Turkey|Local Institution - 0115, Istanbul, 34098, Turkey","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/28/NCT02998528/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/28/NCT02998528/SAP_001.pdf"
